XML 106 R86.htm IDEA: XBRL DOCUMENT v3.6.0.2
Quarterly Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Asset impairments                 $ 1,217 $ 253,560 $ 0
Sales $ 214,372 $ 203,930 $ 247,095 $ 193,757 $ 260,756 $ 264,047 $ 270,252 $ 245,105 859,154 1,040,160 1,192,952
Gross Profit 57,098 69,623 86,951 52,701 72,772 68,289 74,880 72,523 266,373 288,464 357,854
Operating Income (Loss) 2,332 20,064 34,939 37 (238,918) 15,609 25,129 14,957 57,372 [1],[2] (183,223) [3],[4] 138,157
Net income (3,878) 13,684 19,563 (4,672) (231,144) 4,271 17,082 5,275 24,697 (204,516) 83,072
Net income attributable to Chart Industries, Inc. $ (3,290) $ 15,025 $ 21,153 $ (4,651) $ (230,123) $ 4,760 $ 17,157 $ 5,246 $ 28,237 $ (202,960) $ 81,864
Basic $ (0.11) $ 0.49 $ 0.69 $ (0.15) $ (7.54) $ 0.16 $ 0.56 $ 0.17 $ 0.92 [5] $ (6.66) [6] $ 2.69
Diluted $ (0.11) $ 0.48 $ 0.68 $ (0.15) $ (7.54) $ 0.15 $ 0.56 $ 0.17 $ 0.91 [5],[7] $ (6.66) [6],[7] $ 2.67
Escrow Settlement                     $ (5,003)
Cost of Sales [Member]                      
Asset impairments                   $ 1,556  
BioMedical [Member]                      
Operating Income (Loss)                 $ 41,967 $ (165,336) $ 25,009 [8]
BioMedical [Member] | Cost of Sales [Member]                      
Gain (Loss) Related to Litigation Settlement                 15,145    
BioMedical [Member] | Selling, General and Administrative Expenses [Member]                      
Gain (Loss) Related to Litigation Settlement                 $ 376    
[1] (1) During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1,217 attributed to D&S.
[2] The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1,217 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[3] (1) Includes impairment of goodwill and intangible assets totaling $253,560 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4] Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020, and BioMedical - $184,300.
[5] Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[6] (2) Basic and diluted (loss) earnings per share are computed independently for each of the quarters presented. As such, the sum of quarterly basic and diluted (loss) earnings per share may not equal reported annual basic and diluted (loss) earnings per share.
[7] Zero incremental shares from share-based awards are included in the computation of diluted net loss per share for periods in which a net loss occurs, because to do so would be anti-dilutive.
[8] The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.